Nature Cancer – Yang et al. show that transcription–replication collisions lead to large tandem duplications, which are frequent in female-enriched, upper gastrointestinal tract and prostate…
National Comprehensive Cancer Network updated 2 guideline resources to keep providers and other stakeholders up to date on cutting-edge genetic research.
Three Fred Hutch Cancer Center researchers received a five-year, $3.8 million award from the National Cancer Institute to delve into the “black box” of our…
Nutrition & Diabetes – Late eating is associated with poor glucose tolerance, independent of body weight, fat mass, energy intake and diet composition in prediabetes…
The development of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, and ponatinib, has revolutionized the treatment of Ph+ ALL.
Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.
Mark Levis, MD, PhD, John Hopkins University, Baltimore, MD, highlights the favorable tolerability of gilteritinib compared to other FLT3 inhibitors in the post-transplant setting for…
David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.
The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.
Experienced dermatologists provide more accurate diagnoses than inexperienced dermatologists or primary care providers, and the use of in-person examination plus dermoscopy can provide the most…
